Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Dr. Jain on Radioligand Therapy in Prostate Cancer

Manoj K. Jain, MD
Published: Wednesday, Sep 04, 2019



Manoj K. Jain, MD, nuclear medicine specialist, radiologist, Mayo Clinic, discusses the use of radioligand therapy in prostate cancer.

Radioligand therapy with prostate-specific membrane antigen (PSMA) is performed using Lutetium-177 PSMA, which attaches to the prostate cancer cell's surface receptor and is internalized, causing cell destruction, explains Jain.

Radioligand therapy is emerging for patients with metastatic prostate cancer, though it is still investigational in the United States. The therapy is useful for smaller lesions, Jain says, because the particle itself travels about 2 mm once it is within the cell. Radioligand therapy limits the destruction of the normal cell tissue, concludes Jain.
SELECTED
LANGUAGE


Manoj K. Jain, MD, nuclear medicine specialist, radiologist, Mayo Clinic, discusses the use of radioligand therapy in prostate cancer.

Radioligand therapy with prostate-specific membrane antigen (PSMA) is performed using Lutetium-177 PSMA, which attaches to the prostate cancer cell's surface receptor and is internalized, causing cell destruction, explains Jain.

Radioligand therapy is emerging for patients with metastatic prostate cancer, though it is still investigational in the United States. The therapy is useful for smaller lesions, Jain says, because the particle itself travels about 2 mm once it is within the cell. Radioligand therapy limits the destruction of the normal cell tissue, concludes Jain.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x